Table 2.

Logistic regression adjusted odds ratios for associations with attainment of pathological complete response (pCR) among all patients who received neoadjuvant chemotherapy. Significant associations are bolded.

Abbreviations : odds ratio (OR), confidence interval (CI).

	Adjusted OR for achieving pCR
Age
<40 years old	Reference
40–49 years old	0.94 (0.87–1.01)
50–64 years old	0.80 (0.75–0.86)
65 years old and older	0.65 (0.57–0.73)
Race
Non-Hispanic white	Reference
Hispanic	0.99 (0.90–1.08)
Non-Hispanic black	0.96 (0.90–1.03)
Asian/Other	0.88 (0.79–0.98)
Year of Diagnosis
2010	Reference
2011	1.08 (1.00–1.17)
2012	1.22 (1.13–1.33)
2013	1.32 (1.22–1.44)
2014	1.50 (1.39–1.62)
Charlson-Deyo comorbidity score
0	Reference
1	0.92 (0.85–1.00)
2 or higher	0.77 (0.63–0.94)
Residence
Metropolitan	Reference
Urban/Rural	1.10(1.01–1.20)
Distance from reporting facility
Within 50 miles of facility	Reference
>50 miles of facility	1.00 (0.91–1.10)
Education less than high school
21% or more	Reference
13–20.9%	1.03 (0.95–1.12)
7–12.9%	1.05 (0.97–1.13)
<7%	1.04 (0.96–1.14)
Insurance
Medicaid/Not Insureda	Reference
Private/Managed care	1.17 (1.10–1.26)
Medicare	1.11 (0.99–1.25)
Clinical T stage
1–2	Reference
3	0.64 (0.60–0.68)
Clinical N stage
0	Reference
1	0.83 (0.80–0.88)
2	0.85 (0.78–0.94)
3	0.83 (0.73–0.94)
Histology
Ductal	Reference
Lobular or lobular component	0.53 (0.46–0.61)
Other	1.00 (0.88–1.14)
Molecular subtype
ER/PR+, HER2-	Reference
ER/PR+, HER2+	3.15(2.94–3.37)
ER/PR-, HER2+	6.55 (6.03–7.11)
ER/PR-, HER2-	3.39 (3.18–3.61)

^aIncludes Medicaid, uninsured and other government insurance